niagenbioscience.com (NAGE): Rentabilitas operasi

ChromaDex Corporation (NAGE) - logo korporat

The operating profit-to-revenue ratio for Chromadex Corp (NAGE) reflects market expectations, with the current level standing at 2.30. This trend is driven by patent leadership in the Nicotinamide Riboside sector, which creates long-term B2B customer lock-in. Robotic supplement production in sterile zones further enhances efficiency. Meanwhile, the company relies on external chemical synthesis of components, ensuring strict quality control without owning the manufacturing plants.

NAGE - Rasio bathi operasi ChromaDex ing rentang 20.03.2025 - 19.11.2026

Rincian analitis perusahaan Chromadex Corp

- rega saham lan konsensus proyeksi valuasi:
Pambiji fundamental perusahaan:NAGE, ChromaDex
Produk dadi Niagen

Chromadex Corp (NAGE) is scaling its presence in the biohacking segment through the retail expansion of NAD+ supplements. The operating margin reflects the efficiency of profit generation from core operations before accounting for financial expenses and taxes. Analyzing the operating margin allows for an assessment of the business model's real profitability, excluding debt load. Growth in this ratio confirms cost optimization amid increasing sales, while a stable figure indicates the company's fundamental resilience.

Analisis pesaing Chromadex Corp

ISRG (intuitive.com) - Margin operasi|Rentabilitas dodolan miturut bathi operasi DHR (Danaher Corp.)|Margin dodolan operasi BDX (Becton, Dickinson and Company)|Rasio bathi operasi STE|Rentabilitas operasi West Pharma WST|Rentabilitas kegiatan operasi Baxter (BAX)|MASI - Rentabilitas operasi|Rentabilitas kegiatan operasi Stevanato Group Corp STVN|TFX: Margin operasi|Margin dodolan operasi Merit Medical Systems|Rentabilitas operasi Envista Holdings Corp|Margin dodolan operasi ICU Medical Corp (ICUI)|Rentabilitas operasi DENTSPLY SIRONA Inc. (XRAY)|Margin dodolan operasi LeMaitre LMAT|Margin operasi ATRC (atricure.com)|Margin operasi staar.com STAA|ZimVie Inc - Margin operasi|Rentabilitas dodolan operasi AngioDynamics|CERS (Cerus Corp) - Margin dodolan operasi|Alpha Teknova, Inc. - Tingkat bathi operasi|MGRM (Monogram Orthopedics Inc.) - Margin operasi|STSS: Tingkat bathi operasi|Margin dodolan operasi INFU (InfuSystem Holdings)|Utah Medical Products, Inc. - Rentabilitas dodolan miturut bathi operasi|Margin operasi KRMD (korumedical.com)|Rentabilitas kegiatan operasi Nyxoah, S.A. (NYXH)|MBOT - Rentabilitas operasi|PDEX (Pro-Dex, Inc.) - Rentabilitas dodolan miturut bathi operasi|ZTEK (Zentek Ltd) - Margin dodolan operasi|ELUT - Rentabilitas kegiatan operasi|MLSS (Milestone Scientific Corporation) - Margin operasi|Rentabilitas dodolan miturut bathi operasi NXGL (NEXGEL, Inc.)|Margin operasi RVP|Margin dodolan operasi Harvard Bioscience HBIO|Margin operasi FEMY (Femasys Corporation)|MHUA - Margin dodolan operasi|POAI - Rentabilitas operasi|Callan JMB (CJMB) - Margin dodolan operasi|ATRI: Margin operasi|NURO - Rentabilitas kegiatan operasi